Urolithin A vs. Fisetin vs. Spermidine: 2026

Three compounds are dominating longevity conversations in 2026: Urolithin A, Fisetin, and Spermidine. Each approaches cellular aging through a different mechanism. Each has a different evidence base. And each attracts a different kind of buyer -- the rigorous experimenter, the hopeful early adopter, and the dietary supplement minimalist.

This comparison is not about picking a winner. It is about understanding what each compound does, what the evidence actually supports, and how to make an informed decision about whether any of them belongs in your stack.

The Cellular Aging Problem They All Target

To understand why these three supplements are grouped together, you need to understand two related processes: autophagy and cellular senescence.

Autophagy is your cells' internal recycling system. Damaged proteins and dysfunctional organelles -- including mitochondria -- are tagged, engulfed, and broken down for parts. It is the cellular equivalent of waste removal and quality control running simultaneously. Autophagy declines with age, and its decline is associated with the accumulation of cellular junk that contributes to inflammation, metabolic dysfunction, and neurodegeneration.

Cellular senescence is what happens when a damaged cell stops dividing but refuses to die. These cells secrete inflammatory molecules (the SASP -- senescence-associated secretory phenotype) that degrade surrounding tissue and drive chronic inflammation. Clearing them is the job of senolytic compounds.

Urolithin A and Spermidine primarily act as autophagy inducers, with Urolithin A specifically targeting mitochondrial autophagy (mitophagy). Fisetin works primarily as a senolytic -- it clears senescent cells rather than improving how healthy cells maintain themselves. These distinctions matter when you are thinking about what problem you are trying to solve.

Related: Want to put this into practice? Try our Supplement Stack Audit to get started, and check out Anti-Aging Supplements Ranked by Research for more context.

Urolithin A: The Mitophagy Activator with the Strongest Human Data

What It Does

Urolithin A is a postbiotic -- a compound produced by gut bacteria when they metabolize ellagitannins, the polyphenols found in pomegranates, walnuts, and certain berries. Your gut microbiome converts ellagitannins into urolithins, and Urolithin A is the most bioactive form.

Its primary mechanism is the activation of mitophagy -- the selective autophagy of damaged mitochondria. As mitochondria age and accumulate damage, they lose efficiency and begin leaking reactive oxygen species. Mitophagy clears these dysfunctional mitochondria, making room for new, healthy ones. This process is critical for energy metabolism in muscle tissue, and its decline is strongly associated with age-related muscle loss (sarcopenia) and reduced exercise capacity.

The research behind Urolithin A is largely anchored in work by Amazentis, a Swiss biotech that developed Timeline as their consumer brand. Their research, including collaborations with scientists at EPFL, has been instrumental in characterizing Urolithin A's mechanism and conducting the human trials.

The Evidence Base

Urolithin A has the strongest human clinical data of the three compounds discussed here -- not by a small margin.

The pivotal Amazentis trial, published in Nature Metabolism in 2022, was a randomized, double-blind, placebo-controlled study in older adults. Participants taking 1000 mg of Urolithin A daily for four months showed significant improvements in muscle endurance (assessed by hand grip and leg press), increased mitochondrial gene expression in muscle tissue, and improvements in mitophagy biomarkers. A separate trial in middle-aged adults demonstrated improvements in aerobic endurance measured by VO2 max testing.

These are not surrogate biomarker changes in a handful of subjects. They are performance outcomes in randomized controlled trials with peer-reviewed publication. For the longevity supplement space, this is a high bar.

Evidence grade: B+ (human RCTs with functional outcomes; longer-term and larger trials still needed)

Dosing and Practical Notes

• Effective dose: 500-1000 mg daily (most trials used 1000 mg)
• Timing: Can be taken with or without food
• Monthly cost: $60-100 for quality products (Timeline/Amazentis is the most studied brand)
• Safety: Well-tolerated in published trials; no serious adverse events reported

Fisetin: The Senolytic Flavonoid with Promising but Early Human Data

What It Does

Fisetin is a flavonoid found naturally in strawberries, apples, onions, and cucumbers -- though at concentrations far too low to produce therapeutic effects from diet alone. A single kilogram of strawberries contains roughly 160 mg of fisetin; clinical trials use 1500-2000 mg in a pulsed dosing protocol.

Fisetin acts primarily as a senolytic. It selectively induces apoptosis (programmed cell death) in senescent cells while leaving healthy cells intact. The proposed mechanism involves disruption of the pro-survival signaling pathways that senescent cells depend on -- including BCL-2 family proteins and PI3K/AKT. Fisetin also has antioxidant and anti-inflammatory properties, and animal studies suggest it may cross the blood-brain barrier and have neuroprotective effects.

The foundational animal research has been led in part by researchers at the Buck Institute for Research on Aging, with significant contributions from Paul Robbins and Laura Niedernhofer at the University of Minnesota, where the Mayo Clinic clinical program for senolytics has developed. Early fisetin animal data showed extended lifespan and healthspan in mice, reduced brain inflammation, and improved cognitive function in aged animals.

The Evidence Base

Here is where candor is required: the human evidence for fisetin is substantially thinner than for Urolithin A.

The most cited human study is a 2021 pilot trial (AFFIRM-LITE, published in EBioMedicine) that tested 20 mg/kg fisetin for 2 consecutive days in older adults with elevated frailty. The primary endpoints were markers of senescent cells and SASP inflammatory molecules in adipose tissue. Results suggested reductions in some senescent cell markers. However, the trial was small (n=20), was open-label with no placebo control arm, and the clinical significance of the biomarker changes remains unclear.

The honest framing: fisetin has compelling mechanistic rationale and strong animal data. Human trials are active and ongoing. But as of 2026, you would be acting on a hypothesis supported by preclinical evidence and a small pilot study -- not on established clinical outcomes.

Evidence grade: C+ (strong preclinical rationale; human data is early-stage and limited)

Dosing and Practical Notes

• Pulsed protocol: 1500-2000 mg per day for 2 consecutive days, repeated monthly or quarterly
• Daily protocol: Some researchers use 100-200 mg daily, though the intermittent approach mirrors how senolytics are theorized to work
• Absorption: Fisetin has poor oral bioavailability; taking it with a fatty meal improves absorption
• Monthly cost: $20-40 at standard doses (relatively affordable compared to the others)
• Safety: Generally well-tolerated in published studies; drug interactions possible at high doses

Spermidine: The Polyamine with Autophagy-Inducing Properties

What It Does

Spermidine is a polyamine -- a small molecule found in virtually every living cell and in many foods including wheat germ, aged cheese, mushrooms, soy products, and legumes. It is also synthesized endogenously, though cellular levels decline with age.

Its primary longevity mechanism is autophagy induction. Spermidine promotes autophagy through inhibition of EP300, an acetyltransferase enzyme. When EP300 is inhibited, the autophagy regulatory machinery is derepressed. This pathway is mechanistically distinct from rapamycin (mTOR inhibition) or caloric restriction, which means spermidine may have additive effects with those interventions -- though this is not well-tested in humans.

The leading researcher in spermidine biology is Frank Madeo at the University of Graz in Austria. Madeo's lab has published extensively on spermidine's role in autophagy, aging, and longevity across model organisms including yeast, worms, flies, and mice. His work has been foundational in establishing the mechanistic case.

Beyond autophagy, spermidine research has explored effects on cardiovascular health, neurodegeneration, and immune aging. The cardiovascular data in particular has drawn attention.

The Evidence Base

Spermidine sits between Urolithin A (stronger human data) and Fisetin (weaker human data) in terms of clinical evidence, though the framing depends on what outcomes you consider.

A notable observational study published in American Journal of Clinical Nutrition followed thousands of participants over more than 20 years and found that higher dietary spermidine intake was associated with reduced all-cause mortality. This kind of population data is suggestive but cannot establish causation -- people with higher spermidine intake may differ in many other ways.

On the intervention side, a randomized trial in older adults with mild cognitive impairment, conducted by a European research group, found that 12 months of spermidine supplementation produced improvements in memory performance compared to placebo. This is one of the more interesting human findings in the space, though the trial was relatively small.

A double-blind trial in older adults examining cardiovascular markers (supported in part by the Madeo group) showed reductions in several inflammatory and metabolic markers with spermidine supplementation. Again -- intriguing, but not definitive at the level of hard clinical outcomes.

Evidence grade: B- (meaningful human data including one RCT showing cognitive outcomes; large clinical trials still needed)

Dosing and Practical Notes

• Typical supplemental dose: 1-3 mg per day (doses tested in human trials range from 0.9 to 5.7 mg)
• Dietary context: Wheat germ is the densest dietary source at approximately 240 mcg/g; a supplement provides amounts that would be difficult to achieve from diet alone
• Monthly cost: $20-50 for quality products
• Safety: Well-tolerated in published trials; spermidine is endogenous so baseline safety is reasonable, though long-term data is limited

Side-by-Side Comparison

Do They Stack? How These Compounds Work Together

These three compounds work through sufficiently different mechanisms that combining them is theoretically additive rather than redundant:

• Urolithin A drives clearance of damaged mitochondria within cells
• Spermidine promotes broader autophagy of cellular waste
• Fisetin targets senescent cells that autophagy does not clear

There is no published human data on the three-compound combination specifically. Animal work with autophagy inducers and senolytics in combination has been generally positive, but translating that to specific human dosing and timing protocols is speculative.

If you are considering stacking, the practical approach is to establish a baseline with one compound first, assess response over 3-6 months, and then add a second if warranted. Running all three simultaneously at the outset makes it impossible to attribute any change -- positive or negative -- to a specific intervention.

Which to Start With: A Prioritization Framework

If your primary goal is muscle health and energy metabolism: Start with Urolithin A. It has the strongest human RCT evidence, the most clearly defined mechanism for the outcome you care about, and the research is directly relevant to what most men in their 30s and 40s notice first -- reduced recovery, declining endurance, and muscle quality changes.

If your primary goal is brain health and cognitive longevity: Spermidine is the more interesting choice given the cognitive trial data. The dose is small, cost is reasonable, and the mechanistic case for neuronal autophagy is compelling. Fisetin has interesting preclinical neuroprotective data but less human cognitive evidence.

If your primary goal is reducing the inflammatory burden of senescent cells: Fisetin is the most targeted option, though you should enter with eyes open about the early-stage evidence. Alternatively, quercetin + fisetin pulsed monthly is a reasonable low-cost approach.

If you want to start with the highest confidence-to-cost ratio: Urolithin A delivers the clearest human evidence relative to its cost, despite being the most expensive of the three.

What We Still Do Not Know

Honesty about uncertainty is more useful than false confidence:

• Whether the functional improvements seen in Urolithin A trials translate to long-term disease risk reduction
• Whether fisetin's senolytic effects in humans are large enough to matter clinically
• What dietary spermidine intake does relative to supplemental spermidine at the doses used in trials
• Whether combining all three produces additive benefit or complicates individual assessment
• Long-term safety profiles for all three compounds at supplemental doses
• The optimal age to start and whether effects differ between early midlife (28-40) and later midlife (50+)

Related reading

• Rapamycin Alternatives
• Rapamycin for Longevity
• Sun Damage and Skin Aging